Press Release

Tentarix Biotherapeutics Announces Three Collaborations, Plus Acquisition Options With Gilead Sciences

August 15, 2023

San Diego – August 15, 2023 – Cooley advised Tentarix Biotherapeutics and three of its subsidiaries on three multiyear collaborations with Gilead Sciences. Charity Williams and Rama Padmanabhan led the Cooley team advising Tentarix, which also included Lindsey O’Crump, Ritu Gupta, Jameson Davis and Joshua Allen.

The collaboration combines Tentarix’s proprietary Tentacles platform with Gilead’s oncology and inflammation know-how to discover and develop multifunctional, conditional protein therapeutics for oncology and inflammatory diseases. Tentarix will receive upfront payments and an equity investment from Gilead totaling $66 million, with an option for Gilead to acquire the three Tentarix’s subsidiaries containing the programs developed under the collaborations for $80 million per subsidiary.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.